ストックスクリーナーアプリを入手
240.98
0.87%
-2.12
Biogen Inc (BIIB) 最新ニュース
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research
Cisco Systems (CSCO) Stock Price, News & Analysis - 24/7 Wall St.
Lori Trahan Stock Trades and Disclosures - TechGraph
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Form 4 Boeing Co For: 7 October By Investing.com - Investing.com UK
Brookfield Renewable Partners (BEP) Stock Price, News & Analysis - 24/7 Wall St.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Cisco Systems Surges 4.2% to $118.31 in a Single Session - 24/7 Wall St.
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4 - Kalkine Media
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research
Form 4 Boeing Co For: 26 September - Investing.com India
Boeing Company (BA) Stock News & Articles - 247wallst.com
Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com India
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Lilly Builds Neuroscience into a New Long-Term Growth Driver - Zacks Investment Research
Biogen stock heads into the open without fresh price data - ad-hoc-news.de
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Biogen Inc. (BIIB) Investor Outlook: Navigating Growth in the Healthcare Sector with a Potential 7.26% Upside - DirectorsTalk Interviews
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth - ad-hoc-news.de
Biogen Inc. (BIIB) Peer Comparison – Compare with Others - Value Research
Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi - marketscreener.com
0.53%
0.26%
大文字化:
|
ボリューム (24 時間):